Trial Title:
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
NCT ID:
NCT06471465
Condition:
Radionecrosis of Brain
Brain Metastases
Conditions: Official terms:
Neoplasm Metastasis
Brain Neoplasms
Prednisolone
Bevacizumab
Conditions: Keywords:
radionecrosis of brain
brain metastasis
quality of life
bevacizumab
Study type:
Interventional
Study phase:
Phase 3
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
Double (Participant, Investigator)
Intervention:
Intervention type:
Drug
Intervention name:
Bevacizumab
Description:
Drug: bevacizumab IV
Arm group label:
Experimental arm
Other name:
Avastin
Intervention type:
Drug
Intervention name:
Placebo
Description:
Drug: placebo IV
Arm group label:
Placebo arm
Other name:
NaCl
Intervention type:
Drug
Intervention name:
Prednisolone
Description:
Drug: corticosteroids IV
Arm group label:
Experimental arm
Arm group label:
Placebo arm
Other name:
Corticosteroids
Summary:
Brain metastases (BM) afflict a significant portion of cancer patients, ranging from 10%
to 50%, leading to debilitating symptoms and diminished quality of life, thereby
impacting overall survival. Treatment options typically include surgery, stereotactic
radiosurgery (SRS), and whole brain radiotherapy (WBRT). SRS has emerged as the preferred
focal treatment due to its efficacy, delivering ablative doses with notable overall
survival benefits, especially for single BM or postoperative cases, while being less
invasive than neurosurgery and capable of addressing inoperable sites and multiple
lesions. Contrastingly, WBRT is now reserved for select cases with multiple BMs
ineligible for SRS, owing to its lower rate of neurocognitive toxicities and high local
control rates at one year.
Despite its advantages, SRS can engender late side effects, with cerebral radio necrosis
(RN) being the most common, occurring in approximately 10% of patients treated. The exact
pathophysiology of RN remains unclear but is thought to involve vascular injury,
immune-mediated mechanisms, and direct neuronal effects, culminating in radiological
changes or symptomatic manifestations necessitating treatment. Corticosteroids are the
mainstay therapy, albeit with associated side effects and instances of cortico-resistance
or cortico-dependence. Bevacizumab, an anti-VEGF agent, has shown promise in small
studies but awaits validation in larger trials.
Consequently, a randomized phase III trial seeks to evaluate the efficacy of adding
bevacizumab to standard corticosteroid therapy in patients with symptomatic RN. The trial
aims to determine if this combination therapy yields superior symptomatic improvement
compared to corticosteroids alone. RN will be diagnosed using multimodal imaging, and the
primary objective is to assess the efficacy of bevacizumab in reducing corticosteroid
usage and neurological symptoms associated with RN at three months. Secondary endpoints
include toxicities, quality of life, imaging changes, and response duration.
Additionally, an ancillary study will explore correlations between initial imaging
parameters and treatment response, as well as changes in biological parameters with
bevacizumab therapy.
Detailed description:
Brain metastases (BM) are increasingly common in cancer patients; between 10% and 50% (1)
will develop BM resulting in potentially disabling symptoms, degrading quality of life
and impacting overall survival. The main local treatment options include surgery,
hypo-fractionated radiotherapy in stereotactic condition (SRS) and whole brain
radiotherapy (WBRT). Over the past decade, SRS has become the most frequently
administered focal treatment(2). SRS delivers a single or multi-fraction "ablative" dose
as the sole treatment for BM with an overall survival (OS) benefit in patients with
single BM (HR = 0.76; CI95%: 0.66 - 0.88)(3) or postoperatively decreasing the risk of
recurrence (HR = 0.46; CI95%: 0.24 - 0.88)(4). SRS compared to neurosurgery, has the
ability to treat inoperable sites, multiple lesions, and has the advantage of being less
invasive. WBRT is now limited to certain patients with multiple BMs and not eligible for
SRS. SRS is often preferred to WBRT because of a lower rate of neurocognitive toxicities
at 12 months (difference, -34.4%; CI95%: -74.4% to 5.5%; P = .04) for patients with 5 to
10 BMs. Local control at 1 year is high in the order of 90%, and SRS is generally
considered a cost-effective treatment.
However, after SRS there can be late side effects, that can start 3 months to several
years after irradiation, the most common is cerebral radio necrosis (RN) in 10% of
treated patients. The pathophysiology is poorly understood and includes vascular injury,
immune-mediated mechanisms and direct neuronal effects. Vascular injury leads to
increased permeability after radiotherapy resulting in vasogenic oedema and ischemia,
induce hypoxia and an increase in hypoxia inducible factor (HIF-1α) then upregulating
vascular endothelial growth factor (VEGF) which exacerbates the oedema by increasing
vascular permeability which creates a vicious cycle and RN, hence the importance of
inhibiting VEGF(5).
RN may remain as radiological changes (CTCAE v5 grade I toxicity approximately 50%)(6) to
be monitored or be symptomatic (grade II-IV) and requiring treatment. Symptoms are
usually manifested by focal neurological signs and symptoms related to cerebral oedema.
Corticosteroids are the only standard of care before surgery, which is performed when
possible. The problem is that high-dose, long-term corticosteroids have multiple side
effects and some patients with RN may remain symptomatic despite corticosteroid
administration (cortico-resistance) or relapse while decreasing the corticosteroid dose
(cortico-dependence) and no standard treatment is available. Only one small (14 patients)
randomized double-blind study compared bevacizumab 7.5 mg/kg every 3 weeks versus placebo
in RN after irradiation. All 7 patients in the bevacizumab arm had a decrease in FLAIR
oedema volume with clinical improvement in contrast to the placebo arm where everything
worsened(7).
Thus, the anti-VEGF, bevacizumab, is an option but needs to be validated in a phase 3
randomized trial.
This randomized phase III trial aims to determine whether the impact of adding
bevacizumab to standard corticosteroid therapy results in greater symptomatic improvement
than corticosteroid therapy alone in patients with symptomatic RN. RN will be defined by
a multimodal imaging approach combining brain MRI and nuclear medicine imaging (18F-FDOPA
PET or dual phase 18F-FDG PET on CT or MRI). The primary objective of this study is to
investigate whether the addition of bevacizumab to standard corticosteroid therapy,
compared to corticosteroid therapy plus placebo, results in greater efficacy at 3 months
on decrease in corticosteroids and in neurological symptoms associated with radionecrosis
(RN). Secondary endpoints were toxicities, quality of life, PROs (Patient Reported
Outcomes) and Clinician Reported Outcomes (CRO), imaging changes at 3 months, total
weaning of corticosteroids and response duration. An ancillary study will evaluate the
correlation between the initial nuclear medicine imaging parameters and the response to
treatment as well as the evolution of biological parameters under bevacizumab.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patient with a diagnosis of radionecrosis based on a clinical onset of symptoms and
radiological findings of RN following radiotherapy, with or without pathological
confirmation:
MRI evidence to support the diagnosis of RN (transient increase in irradiated lesion
volume -FLAIR hypersignal and/or enhanced portion- without rCBV increase) COMBINED with
nuclear medicine imaging:
biphasic 18FDG-PET-TDM/MRI according to Horky or 18F-FDOPA with stage 0-1 according to
Lizarraga;
- Symptoms are persistent or worsening despite administration of corticosteroids: at
least 1 mg/kg/d of prednisolone or equivalent:
Corticoresistant: neurological symptoms despite administration of at least 2 weeks of 1
mg/kg/d prednisolone or equivalent; Corticodependant: worsening of neurological signs or
symptoms after an initial improvement when weaning off steroids at a dose < 0.5 mg/kg/d
prednisolone or equivalent;
- Patients must have received the last cranial irradiation with photons or proton
therapy for brain metastases ≥ 3 months with one or more sequences;
- Age≥18-year-old;
- ECOG performance status score ≤ 3
- Life expectancy of at least 3 months assessed by graded prognostic score (DS-GPA)
score 0.5 or greater;
- Patient who has never received Bevacizumab for the indication of radionecrosis.
- Adequate organ function:
Bone marrow function
- Absolute Neutrophil Count (ANC) ≥ 1,500/mm3 Platelet Count ≥ 100,000/mm3,
Haemoglobin ≥ 10 g/dL (allowing transfusion or other intervention to achieve this
minimum haemoglobin) Coagulation
- International normalized ratio (INR) or prothrombin time < 1.5 × ULN Renal function
- No proteinuria with urine dipstick for proteinuria > 2+
- Serum creatinine ≤1.5 x ULN or creatinine clearance ≥50 mL/min (measured or
calculated using the CDK-EPI formula) Hepatic Function
- Total bilirubin ≤1.5 x the upper limit of normal (ULN)
- Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤3 x ULN
- Women of childbearing potential must use effective contraceptive measures
during the treatment and for 6 months following its cessation;
- Signed informed consent;
- Patient affiliated to a social security scheme.
Exclusion Criteria:
- Evidence of active bleeding or a pathological condition at high risk of bleeding:
CNS hemorrhage, bleeding diathesis or coagulopathy, hemoptysis (>2.5ml of bright red
blood per episode), evidence of history of bowel obstruction, abdominal fistula, or
gastrointestinal tract perforation or gastro intestinal abscess occurring less than
28 days prior study entry;
- Grade 4 venous thromboelism and peripheral arterial thrombus
- Evidence of very high intracranial pressure that suggests brain hernia and needs
emergency surgery;
- Major surgical procedure or significant traumatic injury less than 28 days prior
study entry; minor surgery within 3 days prior to initiation of study treatment;
- Clinically significant cardiovascular disease such as uncontrolled arterial
hypertension (BP ≥160 mm Hg or diastolic BP ≥100 mm Hg despite maximal medical
therapy), cerebrovascular event, myocardial infarction, cardiac arrhythmias,
unstable angina, or congestive heart failure within the last 6 months;
- History of hypertensive crisis or hypertensive encephalopathy
- Patients scheduled to undergo head and neck, thoracic, or abdominal radiotherapy
during the study treatment
- Prior bevacizumab ≤ 3 months before randomization;
- Progressive brain metastases;
- History of severe allergic anaphylactic reactions to bevacizumab
- Patients with a known hypersensitivity to the active substance or to any of the
excipients of bevacizumab are not eligible for participation;
- Patients with a contraindication to the treatment with bevacizumab according to the
European SmPC
- Patient pregnant and/or nursing;
- Mental impairment (psychiatric illness/social situations) that may compromise the
ability of the patient to give informed consent and comply with the requirements of
the study;
- Patient who has forfeited his/her freedom by administrative or legal award or who is
under guardianship;
- New cerebral metastasis detected during the inclusion imaging evaluation;
- Prior diagnosis of Posterior Reversible Encephalopathy Syndrome (PRES) with
bevacizumab;
- Hypersensitivity known to Chinese Hamster Ovary (CHO) cell products or other
recombinant human or humanised antibodies.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Institut de Cancérologie de l'Ouest
Address:
City:
Saint-Herblain
Zip:
44805
Country:
France
Contact:
Last name:
Luc Ollivier, MD
Email:
luc.ollivier@ico.unicancer.fr
Investigator:
Last name:
luc Ollivier, MD
Email:
Principal Investigator
Start date:
December 2024
Completion date:
December 2029
Lead sponsor:
Agency:
Institut Cancerologie de l'Ouest
Agency class:
Other
Source:
Institut Cancerologie de l'Ouest
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06471465
